Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the ...

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced topline results for two double-blind phase III studies of Dysport® (abobotulinumtoxinA) in Pediatric Lower ...

The FINANCIAL — Allergan plc on August 20 announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s resubmission of its Supplemental Biologics License Application (sBLA) ...

– Dysport is the first and only FDA-approved botulinum toxin for treatment of both pediatric upper and lower limb spasticity1 – – Pivotal Phase 3 study demonstrated Dysport improved spasticity ...

When Dysport was first FDA-approved in 2016 for pediatric lower limb spasticity, Ipsen was granted Orphan Drug exclusivity for pediatric patients whose lower limb spasticity was caused by cerebral ...

— Achieved key co-primary endpoint on efficacy, with 500U dose demonstrating statistically significant difference from placebo in the Modified Ashworth Score (MAS) improvement from baseline — ...

The Food and Drug Administration has approved expanded use of Dysport to treat upper- and lower-limb spasticity – including that caused by cerebral palsy – for patients as young as 2 years and older, ...

Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's resubmission of its Supplemental Biologics ...

As Microsoft CEOs past and present gathered here to celebrate the company's 50th birthday, one leader said he is targeting a particular metric's improvement to guide his strategy on artificial ...

The study used 2016-2020 information from the Pediatric Health Information System (PHIS), an administrative database that includes more than 49 children's hospitals. The authors stratified study ...